Athersys is a clinical stage biopharmaceutical company with a growing pipeline of highly differentiated, potential best in class therapeutics to treat significant and life-threatening diseases. We are engaged in the discovery and development of innovative new medicines designed to extend and enhance the quality of human life. Through the application of our proprietary technologies, we have established a pipeline of therapeutic product development programs in multiple disease areas. This pipeline includes both stem cell therapy and pharmaceuticals.
We are committed to developing therapeutic products that we believe have best-in-class potential, meaning therapeutic candidates that have the potential to be safer, more effective products than the current standard of care or other products in development, and that may have other advantages, such as superior scalability or ease of administration. Our current product development portfolio consists of MultiStem®, a proprietary stem cell product that we are developing as a treatment for multiple disease indications, and that is currently being evaluated in several clinical trials. Areas of interest include evaluating the potential for MultiStem for the treatment of cardiovascular disease (such as treating damage that occurs from a heart attack), immune system disorders (such as inflammatory bowel disease, and Graft versus Host Disease) and neurological conditions (such as damage from an ischemic stroke). In addition, we are developing novel pharmaceuticals to treat indications such as obesity, and related metabolic conditions such as diabetes, as well as certain neurological conditions.
Our strategic approach to drug development builds on internally and externally generated knowledge to identify and develop proprietary and highly differentiated products, as well as enable the company to limit development risks and costs.